Marim Alnaed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marim Alnaed has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Brian S. J. Blagg
Department of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA
1 shared publication - Christopher M. Brackett
South University School of Pharmacy Savannah Giorgia USA
1 shared publication - Kyler W. Pugh
Department of Chemistry and Biochemistry, Warren Family Research Center for Drug Discovery and Development University of Notre Dame Notre Dame Indiana USA
1 shared publication
Latest Publications
- 21 July 2022
- Published by Wiley in Medicinal Research Reviews
- Vol. 42 (6) , 2007-2024
The biology and inhibition of glucose‐regulated protein 94/gp96
The 94 kDa molecular chaperone, glucose‐regulated protein 94 (Grp94), has garnered interest during the last decade due to its direct association with endoplasmic reticulum (ER) stress and disease. Grp94 belongs to the Hsp90 family of molecular chaperones and is a master regulator of ER homeostasis due to its ability to fold and stabilize proteins/receptors, and to chaperone misfolded proteins for degradation. Multiple studies have demonstrated that Grp94 knockdown or inhibition leads to the degradation of client protein substrates, which leads to disruption of disease‐dependent signaling pathways. As a result, small molecule inhibitors of Grp94 have become a promising therapeutic approach to target a variety of disease states. Specifically, Grp94 has proven to be a promising target for cancer, glaucoma, immune‐mediated inflammation, and viral infection. Moreover, Grp94‐peptide complexes have been utilized effectively as adjuvants for vaccines against a variety of disease states. This work highlights the significance of Grp94 biology and the development of therapeutics that target this molecular chaperone in multiple disease states.
- 21 July 2022
- Published by Wiley in Medicinal Research Reviews
- Vol. 42 (6) , 2007-2024
The biology and inhibition of glucose‐regulated protein 94/gp96
The 94 kDa molecular chaperone, glucose‐regulated protein 94 (Grp94), has garnered interest during the last decade due to its direct association with endoplasmic reticulum (ER) stress and disease. Grp94 belongs to the Hsp90 family of molecular chaperones and is a master regulator of ER homeostasis due to its ability to fold and stabilize proteins/receptors, and to chaperone misfolded proteins for degradation. Multiple studies have demonstrated that Grp94 knockdown or inhibition leads to the degradation of client protein substrates, which leads to disruption of disease‐dependent signaling pathways. As a result, small molecule inhibitors of Grp94 have become a promising therapeutic approach to target a variety of disease states. Specifically, Grp94 has proven to be a promising target for cancer, glaucoma, immune‐mediated inflammation, and viral infection. Moreover, Grp94‐peptide complexes have been utilized effectively as adjuvants for vaccines against a variety of disease states. This work highlights the significance of Grp94 biology and the development of therapeutics that target this molecular chaperone in multiple disease states.